




Instance: composition-en-de3f46573279b69427e72992f0f64b7e
InstanceOf: CompositionUvEpi
Title: "Composition for evkeeza Package Leaflet"
Description:  "Composition for evkeeza Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1551/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpde3f46573279b69427e72992f0f64b7e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - evkeeza"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Evkeeza is and what it is used for  </li>
<li>What you need to know before you are given Evkeeza </li>
<li>How Evkeeza is given  </li>
<li>Possible side effects  </li>
<li>How to store Evkeeza </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What evkeeza is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What evkeeza is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Evkeeza is 
Evkeeza contains the active substance evinacumab. It is a type of medicine called a  monoclonal 
antibody . Monoclonal antibodies are proteins that attach to other substances in the body. </p>
<p>What Evkeeza is used for 
Evkeeza is used to treat adults and children aged 5 years and older with very high cholesterol caused 
by a condition called  homozygous familial hypercholesterolaemia . Evkeeza is used with a low-fat 
diet and other medicines to bring down cholesterol levels. </p>
<p>Homozygous familial hypercholesterolaemia runs in families and it is usually passed down by both 
father and mother. </p>
<p>People with this condition have extremely high levels of LDL-cholesterol ( bad cholesterol ) from 
birth. Such high levels can lead to heart attacks, heart valve disease or other problems at an early age. </p>
<p>How does Evkeeza work? 
Evinacumab, the active substance in Evkeeza, attaches to a protein in the body called ANGPTL3 and 
blocks its effects. ANGPTL3 is involved in controlling the production of cholesterol, and blocking its 
effect reduces the production of cholesterol. In this way, Evkeeza can lower blood levels of 
LDL-cholesterol and so prevent problems caused by high LDL-cholesterol levels. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take evkeeza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take evkeeza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You should not be given Evkeeza if: 
* you are allergic to evinacumab or any of the other ingredients of this medicine (listed in 
section 6). 
Warnings and precautions<br />
Talk to your doctor or nurse before you are given Evkeeza. </p>
<p>Look out for serious side effects<br />
Evkeeza can cause serious allergic reactions. 
* Tell your doctor or nurse immediately if you get any symptoms of a severe allergic reaction. 
The symptoms are listed in  Serious side effects  in section 4. Children<br />
Evkeeza is not recommended for children below the age of 5 because there is not yet enough 
information on its use in this group of patients. </p>
<p>Other medicines and Evkeeza 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Pregnancy and contraception 
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for 
advice before taking this medicine. 
* Evkeeza may harm your unborn baby. 
* Tell your doctor immediately if you become pregnant while you are being treated with Evkeeza. </p>
<p>If you are able to become pregnant, you should use effective contraception to avoid becoming 
pregnant. 
* use effective contraception while you are being treated with Evkeeza and 
* use effective contraception for at least 5 months after the last dose of Evkeeza. 
Talk to your doctor about the best contraception method for you during this time. </p>
<p>Breast-feeding 
* If you are breast-feeding or plan to breast-feed, ask your doctor for advice before you are given 
this medicine. 
* It is not known if Evkeeza passes into the breast milk. </p>
<p>Driving and using machines 
Evkeeza is not likely to affect you being able to drive, or use any tools or machines. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take evkeeza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take evkeeza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>How much Evkeeza is given 
Your doctor will work out how much of the medicine to give you. The amount will depend on your 
weight. 
* The recommended dose is 15 milligrams for every kilogram you weigh. 
* You will be given the medicine around once a month. </p>
<p>How Evkeeza is given 
Evkeeza is usually given by a doctor or nurse. It is given as a drip into a vein ( intravenous infusion ) 
over 60 minutes. </p>
<p>If you miss your dose of Evkeeza 
If you have missed an appointment to receive Evkeeza, talk to your doctor or nurse as soon as 
possible. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or nurse. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects 
Severe allergic reactions (uncommon: may affect up to 1 in 100 people) 
Tell your doctor or nurse immediately if you get any of the following symptoms of a severe allergic 
reaction (anaphylactic reaction). The drip will be stopped immediately and you may need to take other 
medicines to control the reaction: 
* swelling   mainly of the lips, tongue or throat, which makes it difficult to swallow or breathe 
* breathing problems or wheezing 
* feeling dizzy or fainting 
* rash, hives 
* itching. </p>
<p>Other side effects 
Tell your doctor or nurse if you notice any of the following side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* symptoms of the common cold, such as runny nose (nasopharyngitis). </p>
<p>Common (may affect up to 1 in 10 people) 
* feeling dizzy 
* sore throat or sinus infection (upper respiratory tract infection) 
* feeling sick (nausea) 
* stomach pain 
* constipation 
* back pain 
* pain in your hands or feet (pain in extremity) 
* symptoms of flu 
* feeling tired or weary (asthenia) 
* infusion reaction, such as itching where the drip is given. </p>
<p>Additional side effects in children aged 5 to 11 years </p>
<p>Very common (may affect more than 1 in 10 people) 
* feeling tired (fatigue). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store evkeeza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store evkeeza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2  C to 8  C). 
Do not freeze. Do not shake. 
Store in the original carton to protect from light. 
Do not use this medicine if you notice it is cloudy, discoloured or contains particulate matter. </p>
<p>Do not store any unused portion of the infusion solution for re-use. Any unused portion of the infusion 
solution should not be re-used and should be disposed in accordance with local requirements. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Evkeeza contains 
* The active substance is evinacumab. 
Each 1 ml of concentrate for solution for infusion contains 150 mg of evinacumab. </p>
<p>Each vial contains either 345 mg of evinacumab in 2.3 ml of concentrate or 1 200 mg of evinacumab 
in 8 ml of concentrate. </p>
<ul>
<li>The other ingredients are proline, arginine hydrochloride, histidine hydrochloride monohydrate, 
polysorbate 80, histidine and water for injections. </li>
</ul>
<p>What Evkeeza looks like and contents of the pack 
Evkeeza concentrate for solution for infusion is a clear to slightly opalescent, colourless to pale yellow 
solution.  </p>
<p>It is available in packs containing either 1 glass vial of 2.3 ml of concentrate or 1 glass vial of 8 ml of 
concentrate. </p>
<p>Marketing Authorisation Holder<br />
Ultragenyx Germany GmbH<br />
Rahel-Hirsch-Str. 10557 Berlin<br />
Germany </p>
<p>Manufacturer 
Ultragenyx Netherlands B. V. 
Evert van de Beekstraat 1, Unit 1118 CL Schiphol 
Netherlands </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:  </p>
<p>BE, BG, CZ, DK, DE, EE, IE, EL, ES, HR, IT, CY, LV, LT, LU, HU, MT, NL, AT, PL, PT, RO, 
SI, SK, FI, SE, XI<br />
Ultragenyx Germany GmbH, DE<br />
Tel/T l/Te ./Tlf/ /Puh/S mi : + 49 30 20179FR<br />
Ultragenyx France SAS, FR<br />
T l: + 33 1 85 65 37 61 ou 0800 917 924 (num ro vert) </p>
<p>This leaflet was last revised in <em>month year</em>. 
This medicine has been authorised under  exceptional circumstances . This means that due to the 
rarity of the disease it has not been possible to obtain complete information on this medicinal product. 
The European Medicines Agency will review any new information which may become available every 
year and this leaflet will be updated as necessary. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu/  </p>
<hr />
<p>The following information is intended for healthcare professionals only: </p>
<p>Traceability </p>
<p>In order to improve the traceability of biological medicinal products, the name and the batch number 
of the administered product should be clearly recorded. </p>
<p>Instructions for use </p>
<p>Preparation of solution 
Evkeeza is supplied as a single use vial only. During preparation and reconstitution a strictly aseptic 
technique should be used. 
* Visually inspect the medicinal product for cloudiness, discolouration or particulate matter prior 
to administration. 
* Discard the vial if the solution is cloudy or discoloured or contains particulate matter. 
* Do not shake the vial. 
* Withdraw the required volume of evinacumab from the vial(s) based on patient s weight and 
transfer into an intravenous infusion bag containing sodium chloride 9 mg/ml (0.9%) or 
dextrose 50 mg/ml (5%) for infusion. Mix the diluted solution by gentle inversion. 
* The final concentration of the diluted solution should be between 0.5 mg/ml to 20 mg/ml. 
* Do not freeze or shake the solution. 
* Discard any unused portion left in the vial. </p>
<p>Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. </p>
<p>After dilution 
Once prepared, administer the diluted solution immediately. If the diluted solution is not administered 
immediately, it may be stored temporarily either: </p>
<ul>
<li>under refrigeration at 2  C to 8  C for no more than 24 hours from the time of infusion 
preparation to the end of the infusion 
or </li>
<li>at room temperature up to 25  C for no more than 6 hours from the time of infusion preparation 
to the end of the infusion. </li>
</ul>
<p>Administration 
* If refrigerated, allow the solution to come to room temperature (up to 25  C) prior to 
administration. 
* Evinacumab should be administered over 60 minutes by intravenous infusion through an 
intravenous line containing a sterile, in-line or add-on 0.2-micron to 5-micron filter. Do not 
administer evinacumab as an intravenous push or bolus. 
* Do not mix other medicinal products with evinacumab or administer concomitantly via the same 
infusion line. </p>
<p>The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of 
adverse reactions, including infusion-associated symptoms. </p> </div>"""      



Instance: composition-da-de3f46573279b69427e72992f0f64b7e
InstanceOf: CompositionUvEpi
Title: "Composition for evkeeza Package Leaflet"
Description:  "Composition for evkeeza Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/21/1551/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpde3f46573279b69427e72992f0f64b7e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - evkeeza"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at få Evkeeza </li>
<li>Sådan får du Evkeeza </li>
<li>Mulige bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Evkeeza 
Evkeeza indeholder det aktive stof evinacumab. Det er en type lægemiddel, der kaldes et "monoklonalt 
antistof". Monoklonale antistoffer er proteiner, der binder sig til andre stoffer i kroppen. </p>
<p>Evkeezas anvendelse 
Evkeeza anvendes til behandling af voksne og børn i alderen 5 år og ældre med meget højt kolesterol, 
der er forårsaget af en tilstand, der kaldes ‘homozygotisk familiær hyperkolesterolæmi’. Evkeeza 
bruges sammen med en kost med lavt fedtindhold og andre lægemidler, til at sænke 
kolesterolniveauerne. </p>
<p>Homozygotisk familiær hyperkolesterolæmi er en arvelig tilstand og den nedarves normalt fra både far 
og mor. </p>
<p>Personer med denne tilstand har ekstremt høje LDL-kolesterolniveauer (‘dårligt kolesterol’) fra 
fødslen. Disse høje niveauer kan medføre hjerteanfald, sygdomme i hjerteklapperne eller andre 
problemer i en tidlig alder. </p>
<p>Hvordan virker Evkeeza? 
Evinacumab, som er det aktive stof i Evkeeza, fæstner sig til et protein i kroppen, der kaldes 
ANGPTL3 og blokerer virkningen af dette. ANGPTL3 er en medvirkende del i styringen af 
kolesterolproduktionen, og blokering af dets virkning reducerer kolesterolproduktionen. På den måde 
kan Evkeeza sænke blodets indhold af LDL-kolesterol og således forebygge problemer, der forårsages 
af høje LDL-kolesterolniveauer. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  evkeeza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  evkeeza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Evkeeza: 
 
hvis du er allergisk over for evinacumab eller et af de øvrige indholdsstoffer i lægemidlet 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller sygeplejersken, før du får Evkeeza. </p>
<p>Hold øje med alvorlige bivirkninger<br />
Evkeeza kan give alvorlige allergiske reaktioner. 
 
Du skal hurtigst muligt fortælle det til lægen eller sygeplejersken, hvis du får nogen symptomer 
på en alvorlig allergisk reaktion. Symptomerne er angivet under "Bivirkninger" i punkt 4. Børn<br />
Evkeeza anbefales ikke til børn i alderen under 5 år, da der endnu ikke er tilvejebragt nok information 
om dets brug hos denne patientgruppe. </p>
<p>Brug af anden medicin sammen med Evkeeza 
Fortæl det altid til lægen, hvis du tager anden medicin, for nylig har taget anden medicin eller 
planlægger at tage anden medicin. </p>
<p>Graviditet og prævention 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du får dette lægemiddel. 
 
Evkeeza kan skade dit ufødte barn. 
 
Fortæl det straks til din læge, hvis du bliver gravid, mens du er i behandling med Evkeeza. </p>
<p>Hvis du kan blive gravid, skal du anvende sikker prævention så du undgår at blive gravid. 
 
anvend sikker prævention, mens du er i behandling med Evkeeza, og 
 
anvend sikker prævention i mindst 5 måneder efter den sidste dosis af Evkeeza. 
Tal med din læge om hvilken præventionsmetode, der er den bedste for dig i denne periode. </p>
<p>Amning 
 
Hvis du ammer eller planlægger at amme, skal du spørge din læge til råds, inden du får dette 
lægemiddel. 
 
Det er ukendt, om Evkeeza udskilles i modermælk. </p>
<p>Trafik- og arbejdssikkerhed 
Evkeeza forventes ikke at påvirke evnen til at føre motorkøretøj eller brug af værktøj eller maskiner. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage evkeeza"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage evkeeza"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvor meget Evkeeza vil du få 
Din læge vil beregne, hvor meget af lægemidlet du skal have. Mængden vil afhænge af din vægt. 
 
Den anbefalede dosis er 15 mg for hvert kilo du vejer. 
 
Du vil få lægemidlet ca. én gang om måneden. </p>
<p>Sådan får du Evkeeza 
Evkeeza gives af en læge eller sygeplejerske. Det bliver givet som et drop i en vene ("en intravenøs 
infusion") over 60 minutter. </p>
<p>Hvis du ikke får din dosis Evkeeza 
Hvis du ikke når din aftalte tid til at få Evkeeza , skal du tale med din læge eller sygeplejerske hurtigst 
muligt. </p>
<p>Spørg lægen eller sygeplejersken, hvis der er noget, du er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger 
Alvorlige allergiske reaktioner (ikke almindelig: kan berøre op til 1 ud af 100 personer) 
Du skal hurtigst muligt fortælle det til lægen eller sygeplejersken, hvis du får nogen symptomer på en 
alvorlig allergisk reaktion ( anafylaktisk reaktion). Infusionen vil omgående blive stoppet, og du kan 
være nødt til at tage andre lægemidler for at kontrollere reaktionen. 
 
hævelser - især af læberne, tungen eller halsen, som gør det svært at synke eller trække vejret 
 
åndenød eller hvæsende vejrtrækning 
 
svimmelhed eller besvimelse 
 
udslæt, nældefeber 
 
kløe. </p>
<p>Andre bivirkninger 
Du skal fortælle det til lægen eller sygeplejersken, hvis du får nogle af de følgende symptomer: </p>
<p>Meget almindelig (kan berøre mere end 1 ud af 10 personer) 
 
symptomer på almindelig forkølelse, som f.eks. løbende næse (nasofaryngitis). </p>
<p>Almindelig (kan berøre op til 1 ud af 10 personer) 
 
svimmelhed 
 
ondt i halsen eller bihulebetændelse (infektion i de øvre luftveje) 
 
kvalme 
 
mavesmerter 
 
forstoppelse 
 
rygsmerter 
 
smerter i dine hænder eller fødder (smerter i ekstremiteterne) 
 
influenzasymptomer 
 
følelse af træthed eller udmattelse (asteni) 
 
infusionsreaktion, som f.eks. kløe, hvor infusionen bliver indgivet. </p>
<p>Yderligere bivirkninger hos børn i alderen 5 til 11 år </p>
<p>Meget almindelig (kan berøre mere end 1 ud af 10 personer) 
 
følelse af træthed (udmattelse). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller sygeplejersken. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette 
bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks 
V*. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og hætteglasset efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 ºC - 8 ºC). 
Må ikke nedfryses. Må ikke omrystes. 
Opbevares i den originale karton for at beskytte mod lys. 
Dette lægemiddel må ikke anvendes, hvis det er uklart, misfarvet eller indeholder partikler. </p>
<p>Opbevar ikke ubrugte portioner af infusionsvæsken med henblik på genbrug. Enhver ubrugt portion af 
infusionsvæsken må ikke genbruges og skal bortskaffes i overensstemmelse med lokale retningslinjer. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Evkeeza indeholder: 
 
Aktivt stof/aktive stoffer: evinacumab. 
Hver ml koncentrat til infusionsvæske, opløsning, indeholder 150 mg evinacumab. </p>
<p>Hvert hætteglas indeholder enten 345 mg evinacumab i 2,3 ml koncentrat eller 1 200 mg evinacumab i 
8 ml koncentrat. </p>
<p> 
Øvrige indholdsstoffer: prolin, argininhydrochlorid, histidine-hydrochloridmonohydrat, 
polysorbat 80, histidin og vand til injektioner. </p>
<p>Udseende og pakningsstørrelser 
Evkeeza koncentrat til opløsning til infusion, er en klar til let opaliserende, farveløs til bleggul 
opløsning.  </p>
<p>Den fås i pakninger indeholdende enten 1 hætteglas med 2,3 ml koncentrat eller 1 hætteglas med 8 ml 
koncentrat. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Ultragenyx Germany GmbH<br />
Rahel-Hirsch-Str. 10<br />
10557 Berlin<br />
Tyskland </p>
<p>Fremstiller 
Ultragenyx Netherlands B. V. 
Evert van de Beekstraat 1, Unit 104 <br />
1118 CL Schiphol<br />
Nederlandene </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:  </p>
<p>BE, BG, CZ, DK, DE, EE, IE, EL, ES, HR, IT, CY, LV, LT, LU, HU, MT, NL, AT, PL, PT, RO, 
SI, SK, FI, SE, XI  </p>
<p>Ultragenyx Germany GmbH, DE<br />
Tel/Tél /Teл./Tlf/Τηλ/Puh/Sími : + 49 30 20179 
FR 
Ultragenyx France SAS, FR<br />
Tél: + 33 1 85 65 37 61 ou 0800 91 79 24 (numéro vert) </p>
<p>Denne indlægsseddel blev senest ændret <em>måned år</em>. 
Dette lægemiddel er godkendt under "særlige vilkår". Det betyder, at det grundet sygdommens 
sjældenhed ikke har været muligt at indhente fuldstændige oplysninger om lægemidlet. Det 
Europæiske Lægemiddelagentur vil hvert år vurdere nye oplysninger om lægemidlet, og indlægssedlen 
vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>
<hr />
<p>Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Sporbarhed </p>
<p>For at forbedre sporbarheden af biologiske lægemidler skal det administrerede produkts navn og 
batchnummer tydeligt registreres. </p>
<p>Brugsanvisning </p>
<p>Klargøring af opløsning til infusion 
Evkeeza leveres kun i hætteglas til engangsbrug. Skal klargøres og rekonstitueres under streng 
overholdelse af aseptisk teknik. 
 
Skal inspiceres visuelt for uklarhed, misfarvning og partikler forud for administration. 
 
I tilfælde af uklarhed, misfarvning eller indhold af fremmedpartikler skal hætteglasset med 
opløsningen kasseres. 
 
Hætteglasset må ikke omrystes. 
 
Træk det påkrævede volumen evinacumab fra hætteglasset(-glassene) baseret på patientens 
vægt, og overfør det til en intravenøs infusionspose indeholdende natriumklorid 9 mg/ml 
(0,9 %) eller glukose 50 mg/ml (5 %) til infusion. Bland den fortyndede opløsning ved at vende 
den forsigtigt. 
 
Den endelige koncentration af den fortyndede opløsning skal være på mellem 0,5 mg/ml til 
20 mg/ml. 
 
Opløsningen må ikke nedfryses eller omrystes. 
 
Kassér enhver ikke-anvendt portion, der er tilbage i hætteglasset. </p>
<p>Ikke-anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinjer. </p>
<p>Efter fortynding 
Når den er klargjort skal den fortyndede opløsning omgående administreres. Hvis den fortyndede 
opløsning ikke administreres omgående, kan den opbevares midlertidigt enten: </p>
<p> 
i køleskab ved 2 ºC til 8 ºC i højst 24 timer fra tidspunktet fra klargøring af infusionsvæsken til 
infusionen afsluttes 
eller 
 
ved stuetemperatur op til 25 ºC i højst 6 timer fra tidspunktet fra klargøring af infusionsvæsken 
til infusionen afsluttes. </p>
<p>Administration 
 
Hvis opløsningen er nedkølet, skal den gives tid til at opnå stuetemperatur (op til 25 ºC) før 
administration. 
 
Evinacumab skal administreres som intravenøs infusion over 60 minutter gennem en intravenøs 
slange indeholdende et sterilt, 0,2-mikron til 5-mikron filter enten i slangen eller påsat denne. 
Evinacumab må ikke administreres intravenøst på én gang eller som en bolus. 
 
Andre lægemidler må ikke blandes med evinacumab eller administreres samtidig gennem den 
samme infusionsslange. </p>
<p>Infusionshastigheden kan sænkes, afbrydes eller seponeres, hvis patienten udvikler tegn på 
bivirkninger, herunder symptomer i forbindelse med infusionen. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-de3f46573279b69427e72992f0f64b7e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for evkeeza Package Leaflet for language en"
Description: "ePI document Bundle for evkeeza Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-de3f46573279b69427e72992f0f64b7e"
* entry[0].resource = composition-en-de3f46573279b69427e72992f0f64b7e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpde3f46573279b69427e72992f0f64b7e"
* entry[=].resource = mpde3f46573279b69427e72992f0f64b7e
                            
                    
Instance: bundlepackageleaflet-da-de3f46573279b69427e72992f0f64b7e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for evkeeza Package Leaflet for language da"
Description: "ePI document Bundle for evkeeza Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-de3f46573279b69427e72992f0f64b7e"
* entry[0].resource = composition-da-de3f46573279b69427e72992f0f64b7e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpde3f46573279b69427e72992f0f64b7e"
* entry[=].resource = mpde3f46573279b69427e72992f0f64b7e
                            
                    



Instance: mpde3f46573279b69427e72992f0f64b7e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Evkeeza 150 mg/ml concentrate for solution for infusion"
Description: "Evkeeza 150 mg/ml concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1551/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Evkeeza 150 mg/ml concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: de3f46573279b69427e72992f0f64b7eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "evkeeza"

* status = #current
* mode = #working

* title = "List of all ePIs associated with evkeeza"

* subject = Reference(mpde3f46573279b69427e72992f0f64b7e)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#evkeeza "evkeeza"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-de3f46573279b69427e72992f0f64b7e) // evkeeza en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-de3f46573279b69427e72992f0f64b7e) // evkeeza da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-de3f46573279b69427e72992f0f64b7e
InstanceOf: List
Description: "ePI document List for evkeeza Package Leaflets"

* insert de3f46573279b69427e72992f0f64b7eListRuleset
    